BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18711188)

  • 1. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
    Manegold C; Gravenor D; Woytowitz D; Mezger J; Hirsh V; Albert G; Al-Adhami M; Readett D; Krieg AM; Leichman CG
    J Clin Oncol; 2008 Aug; 26(24):3979-86. PubMed ID: 18711188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.
    Hirsh V; Paz-Ares L; Boyer M; Rosell R; Middleton G; Eberhardt WE; Szczesna A; Reiterer P; Saleh M; Arrieta O; Bajetta E; Webb RT; Raats J; Benner RJ; Fowst C; Meech SJ; Readett D; Schiller JH
    J Clin Oncol; 2011 Jul; 29(19):2667-74. PubMed ID: 21632509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
    J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
    Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
    J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
    Felip E; Rosell R; Maestre JA; Rodríguez-Paniagua JM; Morán T; Astudillo J; Alonso G; Borro JM; González-Larriba JL; Torres A; Camps C; Guijarro R; Isla D; Aguiló R; Alberola V; Padilla J; Sánchez-Palencia A; Sánchez JJ; Hermosilla E; Massuti B;
    J Clin Oncol; 2010 Jul; 28(19):3138-45. PubMed ID: 20516435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
    Kubota K; Watanabe K; Kunitoh H; Noda K; Ichinose Y; Katakami N; Sugiura T; Kawahara M; Yokoyama A; Yokota S; Yoneda S; Matsui K; Kudo S; Shibuya M; Isobe T; Segawa Y; Nishiwaki Y; Ohashi Y; Niitani H;
    J Clin Oncol; 2004 Jan; 22(2):254-61. PubMed ID: 14722033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
    Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
    J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
    J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
    Scagliotti G; Novello S; von Pawel J; Reck M; Pereira JR; Thomas M; Abrão Miziara JE; Balint B; De Marinis F; Keller A; Arén O; Csollak M; Albert I; Barrios CH; Grossi F; Krzakowski M; Cupit L; Cihon F; Dimatteo S; Hanna N
    J Clin Oncol; 2010 Apr; 28(11):1835-42. PubMed ID: 20212250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
    J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
    Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
    J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
    Soria JC; Márk Z; Zatloukal P; Szima B; Albert I; Juhász E; Pujol JL; Kozielski J; Baker N; Smethurst D; Hei YJ; Ashkenazi A; Stern H; Amler L; Pan Y; Blackhall F
    J Clin Oncol; 2011 Nov; 29(33):4442-51. PubMed ID: 22010015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
    Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
    Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
    Leighl NB; Paz-Ares L; Douillard JY; Peschel C; Arnold A; Depierre A; Santoro A; Betticher DC; Gatzemeier U; Jassem J; Crawford J; Tu D; Bezjak A; Humphrey JS; Voi M; Galbraith S; Hann K; Seymour L; Shepherd FA
    J Clin Oncol; 2005 Apr; 23(12):2831-9. PubMed ID: 15837997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
    Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
    Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer.
    Carter DL; Garfield D; Hathorn J; Mundis R; Boehm KA; Ilegbodu D; Asmar L; Reynolds C
    Clin Lung Cancer; 2012 May; 13(3):205-13. PubMed ID: 22138037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
    Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP
    J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
    Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY
    J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.